Exploring the Mystery of EBV and Tumor 丨Hengsai Biotechnology Shows Its Elegance on the International Academic Stage Again

As a biotechnology company dedicated to immunotherapy, the research team of Hengsai Biotechnology brought a new hope for the treatment of EBV-associated tumors in this international event, which aroused great interest from the experts attending the meeting. The results of the preliminary clinical study of KSD-101 vaccine in the treatment of hematological oncology are exciting, which not only showed good safety and efficacy, but also, more importantly, provided a new vision and possibility for EBV-associated blood diseases for which there is no standard treatment at the moment. More importantly, it provides a new vision and possibility for EBV-related hematologic diseases for which there is no standard treatment at present. Its exhibition topics"Dendritic cell vaccine against EBV-associated hematologic tumors (KSD-101): results of an ongoing phase I clinical study(Dendritic Cell-Based Vaccines (KSD-101) Against EBV-Associated Hematologic Neoplasms: Results from an ongoing Phase I Clinical Study)"The KSD-101 has become a hot spot in the conference room as soon as it was unveiled, and the experts praised KSD-101 for its ingenious scientific design and extraordinary dexterity!